CHARGE: 502(a)—when shipped and while held for sale, the labeling of the article contained false and misleading representations that the article was an adequate and effective treatment for gout, sclerosis, kidney disease, articular inflammation, headache, bladder troubles, swelling of the prostate gland, kidney stones and gravel, inflammation of the kidney, gastric hyperacidity, gastric ulcer, colitis, ulcer of the bowels, gastric and intestinal catarrh, bad taste in the mouth, bellyache, enteritis, bilious attacks, gallstones, liver complaints, jaundice, decrepitude and bodily weakness, neurasthenia, nervousness, fainting, nervous debility, catarrhs of the bronchia or lungs, catarrh of the throat, difficult breathing, goiter hyperthyroidism, Basedow's disease, diabetes, rheumatism, pain in the joints, lumbago, contagious diseases, grippe, inflammation, impure blood, women's diseases, diseases of adolescence, scrofula, malfunctioning of the glands of the internal secretion, and for preventing bad effects due to excessive drinking and eating.

DISPOSITION: 4–29–59. Default—destruction.

5924. Eucalyptus oil compound. (F.D.C. No. 42884. S. No. 35–856 P.)

QUANTITY: 47 2-oz. btls., 31 8-oz. btls., and 27 4-oz. btls., at Philadelphia, Pa.

SHIPPED: 1–28–59, from Pitman, N.J., by Pitman Chemical Laboratories, Inc.

LABEL IN PART: "Mustiez Eucalyptus Oil Compound * * * 100% U.S.P. or N.F. Oil Eucalyptus, Methyl Salicylate, Gum Camphor, Peppermint, Thymol, Menthol. * * * Mustiez Products, Box 311, Trevose, Pa."

ACCOMPANYING LABELING: Leaflets entitled "Mustiez Eucalyptus Oil Compound."

LIBELED: 3–13–59, E. Dist. Pa.

CHARGE: 502(a)—when shipped, the labeling accompanying the article contained false and misleading representations that the article was an adequate and effective treatment for arthritis, rheumatism, sciatica, bursitis, lumbago, sinusitis, and "irritation."

DISPOSITION: 4–15–59. Default—destruction.

5925. Amphetamine tablets. (F.D.C. No. 42952. S. No. 15–647 P.)

QUANTITY: 24 btls. at Dayton, Ohio.

SHIPPED: 9–20–58, from Philadelphia, Pa., by J. W. S. Delavau Co., Inc.

LABEL IN PART: "Four Amphetamines 2.5 Mg. each tablet contains: Phenobarbital ¼ gr. * * * Racemic Amphetamine 2.5 Mg. Dextroamphetamine 2.5 Mg. Methamphetamine 2.5 Mg. Methamphetamine Pot. Saccharate 2.5 Mg. * * * Manufactured for Halsom Drug Co., Dayton, Ohio."

RESULTS OF INVESTIGATION: Analysis showed that the article contained 62 percent of the labeled amount of total amphetamines and 28 percent of the labeled amount of phenobarbital.

LIBELED: 3–26–59, S. Dist. Ohio.

CHARGE: 502(a)—when shipped, the label statement "Each tablet contains: Phenobarbital ¼ gr. * * * Racemic Amphetamine 2.5 Mg. Dextroamphetamine 2.5 Mg. Methamphetamine 2.5 Mg. Methamphetamine Pot. Saccharate 2.5 Mg." was false and misleading.

DISPOSITION: 4–22–59. Default—destruction.

5926. Groff's Artha-Tone. (F.D.C. No. 42312. S. No. 41–293 P.)

QUANTITY: 29 50-tablet btls., 42 100-tablet btls., and 9 250-tablet btls., at Tacoma, Wash.